RMB (RENCA Macrobead) therapy in advanced mCRC: Phase IIb preliminary multi-site survival findings; correlation & combination with Phase I and IIa data including imaging and lab profiles [U.S.FDA BB-IND 10091]

Abstract

associated with shorter ePFS (p ¼ 0.029). In the subgroup of patients who did not undergo metastases' resection in their disease history (N ¼ 61), ECOG PS 0 (p ¼ 0.024), longest diameter of liver lesions < 30 mm (p ¼ 0.011) and left-sidedness (p ¼ 0.081) were independently associated with longer ePFS. Conclusion: In this contemporary cohort, the vast majority of mCRC patients with initially unresectable liver-limited disease underwent surgical procedures (73%) and further locoregional interventions (40%) in their disease history. ECOG PS, number and diameter of liver metastases, and sidedness independently predict ePFS. These factors could help physicians in personalizing the intensity and aggressiveness of liver directed treatments in mCRC patients with initially unresectable liver-limited disease.PD À 018 Comparing survival in left-sided and right-sided colorectal carcinoma: A Belgian population-based study